Kiyoshi Takatsuki

Summary

Affiliation: Kitano Hospital
Country: Japan

Publications

  1. ncbi Discovery of adult T-cell leukemia
    Kiyoshi Takatsuki
    Department of Internal Medicine II, Kumamoto University School of Medicine, 1 1 1 Honjo, Kumamoto 860 8556, Japan
    Retrovirology 2:16. 2005
  2. ncbi Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia
    Akane Kunitomi
    Department of Medicine, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan
    Int J Hematol 80:246-9. 2004
  3. ncbi [Contribution of Japanese researchers to progress in the field of hematology in the last 100 years: Adult T-cell leukemia-lymphoma]
    Kiyoshi Takatsuki
    Nippon Naika Gakkai Zasshi 91:2054-6. 2002
  4. ncbi Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109)
    Kunihiro Tsukasaki
    Nagasaki University, Nagasaki, Japan
    Int J Hematol 77:164-70. 2003
  5. ncbi Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study
    Kensuke Usuki
    Division of Hematology, NTT Kanto Medical Center, Tokyo, Japan
    Br J Haematol 116:103-12. 2002
  6. ncbi Management of patients with multiple myeloma in Japan: data of 1,383 patients from 16 hospitals and 1 treatment group
    Kazuyuki Shimizu
    Nagoya City Midori General Hospital, Japan
    Leuk Lymphoma 45:2465-9. 2004
  7. ncbi Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group
    Chihiro Shimazaki
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 620 9566, Japan
    Int J Hematol 81:342-8. 2005
  8. ncbi Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma
    Hirokazu Murakami
    School of Health Sciences, Faculty of Medicine, Gunma University, Gunma, Japan
    Eur J Haematol 79:234-9. 2007

Collaborators

  • Norihiro Nishimoto
  • Akane Kunitomi
  • Tadamitsu Kishimoto
  • Kensei Tobinai
  • K Tsukasaki
  • Hirokazu Murakami
  • Yasuaki Yamada
  • Shinsuke Iida
  • Nobuyuki Hamajima
  • Chihiro Shimazaki
  • Kazuyuki Shimizu
  • Kensuke Usuki
  • Tadao Ishida
  • Takashi Yoshida
  • Hiroshi Fujii
  • Masafumi Taniwaki
  • Takaaki Chou
  • Hideki Asaoku
  • Toshiyuki Takagi
  • Miki Nishimura
  • Shuichi Miyawaki
  • Akihiro Ishii
  • Eiichi Nagura
  • Atsushi Kuramoto
  • Yousirou Niitsu
  • Ikurou Kimura
  • Haruto Uchino
  • Minoru Ohkuma
  • Hideaki Mizoguchi
  • Masao Tomonaga
  • Takeo Nomura
  • Tadami Nagao
  • Tsukasa Abe
  • Tamotsu Miyazaki
  • Yasusada Miura
  • Toru Nakamura
  • Fumimaro Takaku
  • Akio Urabe
  • Atsushi Horiuchi
  • Yasuo Ikeda
  • Shigeru Shirakawa
  • Hidehiko Saitou
  • Akira Miura
  • Tamotsu Matsuda
  • Akira Shibata
  • Ryuzo Ohno
  • Toru Masaoka
  • Yutaka Yoshida
  • Yoshiyuki Niho
  • Syozo Irino

Detail Information

Publications8

  1. ncbi Discovery of adult T-cell leukemia
    Kiyoshi Takatsuki
    Department of Internal Medicine II, Kumamoto University School of Medicine, 1 1 1 Honjo, Kumamoto 860 8556, Japan
    Retrovirology 2:16. 2005
    ..Moreover, it was noted that an immunodeficiency state may be induced by HTLV-1 infection. In Japan, HTLV-1 carriers have been estimated to be 1.2 million, and more than 700 cases of ATL have been diagnosed each year...
  2. ncbi Humanized anti-interleukin 6 receptor antibody induced long-term remission in a patient with life-threatening refractory autoimmune hemolytic anemia
    Akane Kunitomi
    Department of Medicine, Kitano Hospital, The Tazuke Kofukai Medical Research Institute, Osaka, Japan
    Int J Hematol 80:246-9. 2004
    ..After 2 years of MRA treatment, the disease activity was well controlled without adverse reactions. Anti-IL-6R MoAb can be a novel and effective therapeutic agent for AIHA...
  3. ncbi [Contribution of Japanese researchers to progress in the field of hematology in the last 100 years: Adult T-cell leukemia-lymphoma]
    Kiyoshi Takatsuki
    Nippon Naika Gakkai Zasshi 91:2054-6. 2002
  4. ncbi Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109)
    Kunihiro Tsukasaki
    Nagasaki University, Nagasaki, Japan
    Int J Hematol 77:164-70. 2003
    ..We conclude that DCF-containing combination chemotherapy is not a promising regimen against aggressive ATL...
  5. ncbi Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study
    Kensuke Usuki
    Division of Hematology, NTT Kanto Medical Center, Tokyo, Japan
    Br J Haematol 116:103-12. 2002
    ..0001). In conclusion, prophylactic administration of G-CSF after remission induction therapy for acute myelogenous leukaemia is safe and useful even in patients without infection on completing chemotherapy...
  6. ncbi Management of patients with multiple myeloma in Japan: data of 1,383 patients from 16 hospitals and 1 treatment group
    Kazuyuki Shimizu
    Nagoya City Midori General Hospital, Japan
    Leuk Lymphoma 45:2465-9. 2004
    ..1 years. High-dose therapy followed by stem cell transplantation (SCT) as part of first-line therapy was given in 113 (7.4%) patients with median survival being 4.4 years...
  7. ncbi Reduced-intensity conditioning allogeneic stem cell transplantation for multiple myeloma: results from the Japan Myeloma Study Group
    Chihiro Shimazaki
    Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto 620 9566, Japan
    Int J Hematol 81:342-8. 2005
    ..5% and 18.8%, respectively. These observations suggest that RIST is feasible with reliable donor engraftment and relatively low transplantation-related mortality in Japanese MM patients...
  8. ncbi Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma
    Hirokazu Murakami
    School of Health Sciences, Faculty of Medicine, Gunma University, Gunma, Japan
    Eur J Haematol 79:234-9. 2007
    ..Leukopenia is one of the most serious adverse events in Japanese patients, especially in patients with pretreatment pancytopenia...